Novartis AG chief executive Vas Narasimhan said his Sandoz generics unit’s malaria, lupus and arthritis drug hydroxychloroquine is the company’s biggest hope against COVID-19, Swiss weekly SonntagsZeitung reported yesterday.
Novartis has pledged to donate 130 million doses and is supporting clinical trials needed before the medicine, which US President Donald Trump also has been promoting, can be approved for use.
Other companies including Bayer AG and Teva Pharmaceutical Industries Ltd have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences Inc is testing its experimental drug remdesivir against COVID-19.
“Pre-clinical studies in animals, as well as the first data from clinical studies, show that hydroxychloroquine kills the coronavirus,” Narasimhan told the newspaper. “We’re working with Swiss hospitals on possible treatment protocols for the clinical use of the drug, but it’s too early to say anything definitively.”
He said the company is currently looking for additional active drug ingredients to make more hydroxychloroquine, should clinical trials be successful.
Narasimhan said that three other Novartis drugs — Jakavi for cancer, multiple sclerosis drug Gilenya and fever drug Ilaris — are being studied for their effect on complications related to COVID-19, SonntagsZeitung reported.
This follows efforts to repurpose drugs made by Roche Holding AG and Sanofi SA to treat complications related to the disease.
Meanwhile, Gilead is to expand access to its experimental anti-coronavirus drug remdesivir to accelerate its emergency use for multiple severely ill patients.
The drugmaker said it is switching to “expanded access” from a “compassionate use” program under which remdesivir was given to more than 1,000 COVID-19 patients.
“With expanded access, hospitals or physicians can apply for emergency use of remdesivir for multiple severely ill patients at a time,” Gilead chairman and CEO Daniel O’Day said in an open letter sent by e-mail on Saturday.
“While it will take some time to build a network of active sites, this approach will ultimately accelerate emergency access for more people,” he said.
Remdesivir was developed initially for Ebola and studied in patients in the eastern region of the Democratic Republic of the Congo. Multiple clinical trials are investigating the drug’s effects in COVID-19 patients in China and elsewhere.
Initial results might be reported in the coming weeks, O’Day said.
If approved, the Foster City, California-based company “will work to ensure affordability and access, so that remdesivir is available to patients with the greatest need,” he said.
“The urgency comes from knowing the desperate need among patients and the lack of any approved treatment,” O’Day said. “The responsibility is to ensure that remdesivir, an investigational medicine, is effective and safe before it is distributed for use worldwide,” he said.
Additional reporting by Bloomberg
Intel Corp chief executive officer Lip-Bu Tan (陳立武) is expected to meet with Taiwanese suppliers next month in conjunction with the opening of the Computex Taipei trade show, supply chain sources said on Monday. The visit, the first for Tan to Taiwan since assuming his new post last month, would be aimed at enhancing Intel’s ties with suppliers in Taiwan as he attempts to help turn around the struggling US chipmaker, the sources said. Tan is to hold a banquet to celebrate Intel’s 40-year presence in Taiwan before Computex opens on May 20 and invite dozens of Taiwanese suppliers to exchange views
Application-specific integrated circuit designer Faraday Technology Corp (智原) yesterday said that although revenue this quarter would decline 30 percent from last quarter, it retained its full-year forecast of revenue growth of 100 percent. The company attributed the quarterly drop to a slowdown in customers’ production of chips using Faraday’s advanced packaging technology. The company is still confident about its revenue growth this year, given its strong “design-win” — or the projects it won to help customers design their chips, Faraday president Steve Wang (王國雍) told an online earnings conference. “The design-win this year is better than we expected. We believe we will win
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) is expected to share his views about the artificial intelligence (AI) industry’s prospects during his speech at the company’s 37th anniversary ceremony, as AI servers have become a new growth engine for the equipment manufacturing service provider. Lam’s speech is much anticipated, as Quanta has risen as one of the world’s major AI server suppliers. The company reported a 30 percent year-on-year growth in consolidated revenue to NT$1.41 trillion (US$43.35 billion) last year, thanks to fast-growing demand for servers, especially those with AI capabilities. The company told investors in November last year that
Power supply and electronic components maker Delta Electronics Inc (台達電) yesterday said it plans to ship its new 1 megawatt charging systems for electric trucks and buses in the first half of next year at the earliest. The new charging piles, which deliver up to 1 megawatt of charging power, are designed for heavy-duty electric vehicles, and support a maximum current of 1,500 amperes and output of 1,250 volts, Delta said in a news release. “If everything goes smoothly, we could begin shipping those new charging systems as early as in the first half of next year,” a company official said. The new
RSS